NCT03656692 - Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2018

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions

Uveitis, PosteriorUveitis, IntermediatePanuveitis

Interventions

DRUG

Acthar Gel

Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)

Trial Locations (8)

Virginia Eye Consultants, Norfolk

Blue Ocean Clinical Research, Clearwater

Midwest Eye Institute, Indianapolis

Bergstrom Eye Research, LLC, Fargo

Foresight Studies, LLC, San Antonio

Valley Retina Institute, PA, McAllen

Massachusetts Eye Research and Surgery Institution (MERSI), Waltham

Metropolitan Eye Research and Surgery Institute, Palisades Park